DIABETIC MACULAR EDEMA;

. OBJECTIVE: To evaluate the effect of Intravitreal Bevacuzimab on Best CorrectedVisual Acuity in patients with clinically significant diabetic macular edema. MATERIAL ANDMETHODS: A prospective uncontrolled interventional case series in which 42 eyes of 31consecutive diabetic patients with clinically significant macular edema and no significantcomorbid ocular association presenting in the outpatients department of Holy Family Hospitaland EYE SURGERY clinic, Rawalpindi Pakistan and opting for the treatment from 1st September2013 to 31st January 2014 were given an intravitreal injection of Bevacizumab. BCVA wasdocumented prior to and four weeks after the injection. Main outcome measure was changes inBCVA. RESULTS: Out of the 31 patients included in the study 14(45.16%) were male and 17(54.83%) female. Average age was 56.1 ± 7.6. All 31 patients (42 eyes) came for follow up andtheir BCVA recorded. 41 (97.61%) eyes showed an improvement of one or more line on Snellen'schart at 4 weeks. 14 (33.33%) eyes showed an improvement of one line, 19 (45.23%) eyes animprovement of two lines, 6 (14.28%) eyes three lines and just 2 (4.76%) eyes had animprovement of four lines on Snellen's chart at 4 weeks. Only 1(2.38%) eye remained same withno worsening. On logMAR conversion scale for Snellen's letters the BCVA improved from 0.76 ±0.27 to 0.47 ± 0.27 (p< 0.001). No significant complications were observed in any of the eyes.CONCLUSION: The use of intravitreal Bevacizumab (1.25mg/0.05ml) is a safe and effective moeof treatment for clinically significant diabetic macular edema.